Published in Chem Commun (Camb) on January 04, 2011
Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov (2006) 4.39
Bacterial toxins: a table of lethal amounts. Microbiol Rev (1982) 3.74
Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol (2004) 3.69
Identification and prediction of promiscuous aggregating inhibitors among known drugs. J Med Chem (2003) 3.44
A detergent-based assay for the detection of promiscuous inhibitors. Nat Protoc (2006) 2.58
Identification of a potent botulinum neurotoxin a protease inhibitor using in situ lead identification chemistry. Org Lett (2006) 1.81
The strange case of the botulinum neurotoxin: using chemistry and biology to modulate the most deadly poison. Angew Chem Int Ed Engl (2008) 1.80
SNARE motif and neurotoxins. Nature (1994) 1.62
Toward the discovery of potent inhibitors of botulinum neurotoxin A: development of a robust LC MS based assay operational from low to subnanomolar enzyme concentrations. Chem Commun (Camb) (2008) 1.37
Bimodal modulation of the botulinum neurotoxin protein-conducting channel. Proc Natl Acad Sci U S A (2009) 1.26
High-throughput fluorogenic assay for determination of botulinum type B neurotoxin protease activity. Anal Biochem (2001) 1.21
Botulinum neurotoxin A protease: discovery of natural product exosite inhibitors. J Am Chem Soc (2010) 1.14
Substrate recognition of VAMP-2 by botulinum neurotoxin B and tetanus neurotoxin. J Biol Chem (2008) 1.11
Receptor and substrate interactions of clostridial neurotoxins. Toxicon (2009) 1.01
Chirality holds the key for potent inhibition of the botulinum neurotoxin serotype a protease. Org Lett (2010) 0.99
Efficacy of a novel metalloprotease inhibitor on botulinum neurotoxin B activity. FEBS Lett (1998) 0.95
Use of a recombinant fluorescent substrate with cleavage sites for all botulinum neurotoxins in high-throughput screening of natural product extracts for inhibitors of serotypes A, B, and E. Appl Environ Microbiol (2007) 0.94
L-chicoric acid inhibits human immunodeficiency virus type 1 integration in vivo and is a noncompetitive but reversible inhibitor of HIV-1 integrase in vitro. Virology (2004) 0.92
HPLC method validated for the simultaneous analysis of cichoric acid and alkamides in Echinacea purpurea plants and products. J Agric Food Chem (2003) 0.91
Dicaffeoyltartaric acid analogues inhibit human immunodeficiency virus type 1 (HIV-1) integrase and HIV-1 replication at nontoxic concentrations. J Med Chem (2002) 0.90
Small tripeptide surrogates with low nanomolar affinity as potent inhibitors of the botulinum neurotoxin B metallo-proteolytic activity. Bioorg Med Chem (2004) 0.89
Synthetic substrate for application in both high and low throughput assays for botulinum neurotoxin B protease inhibitors. Bioorg Med Chem Lett (2009) 0.85
Development of potent inhibitors of botulinum neurotoxin type B. J Med Chem (2003) 0.84
On the active site of elastase: Partial mapping by means of specific peptide substrates. FEBS Lett (1970) 0.83
Partial protection against Botulinum B neurotoxin-induced blocking of exocytosis by a potent inhibitor of its metallopeptidase activity. Chembiochem (2005) 0.82
Thio-derived disulfides as potent inhibitors of botulinum neurotoxin type B: implications for zinc interaction. Bioorg Med Chem (2003) 0.82
The pentacovalent phosphorus intermediate of a phosphoryl transfer reaction. Science (2003) 3.41
Evolutionary genomics of the HAD superfamily: understanding the structural adaptations and catalytic diversity in a superfamily of phosphoesterases and allied enzymes. J Mol Biol (2006) 3.10
Evidence for antibody-catalyzed ozone formation in bacterial killing and inflammation. Science (2002) 2.51
Infection control by antibody disruption of bacterial quorum sensing signaling. Chem Biol (2007) 2.24
Evidence for ozone formation in human atherosclerotic arteries. Science (2003) 2.22
Revisiting quorum sensing: Discovery of additional chemical and biological functions for 3-oxo-N-acylhomoserine lactones. Proc Natl Acad Sci U S A (2004) 2.05
Modulation of gene expression via disruption of NF-kappaB signaling by a bacterial small molecule. Science (2008) 1.93
The Enzyme Function Initiative. Biochemistry (2011) 1.87
An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists. Proc Natl Acad Sci U S A (2007) 1.85
Identification of a potent botulinum neurotoxin a protease inhibitor using in situ lead identification chemistry. Org Lett (2006) 1.81
The strange case of the botulinum neurotoxin: using chemistry and biology to modulate the most deadly poison. Angew Chem Int Ed Engl (2008) 1.80
Deeply inverted electron-hole recombination in a luminescent antibody-stilbene complex. Science (2008) 1.79
Synthesis, characterization and development of a high-throughput methodology for the discovery of botulinum neurotoxin a inhibitors. J Comb Chem (2006) 1.79
Structures of Clostridium botulinum Neurotoxin Serotype A Light Chain complexed with small-molecule inhibitors highlight active-site flexibility. Chem Biol (2007) 1.78
Treating cocaine addiction with viruses. Proc Natl Acad Sci U S A (2004) 1.75
Uncharacterized 4,5-dihydroxy-2,3-pentanedione (DPD) molecules revealed through NMR spectroscopy: implications for a greater signaling diversity in bacterial species. Angew Chem Int Ed Engl (2012) 1.55
Fluorescent cocaine probes: a tool for the selection and engineering of therapeutic antibodies. J Am Chem Soc (2005) 1.48
Targeting heat shock proteins on cancer cells: selection, characterization, and cell-penetrating properties of a peptidic GRP78 ligand. Biochemistry (2006) 1.48
A vaccine strategy that induces protective immunity against heroin. J Med Chem (2011) 1.47
Vaccination against weight gain. Proc Natl Acad Sci U S A (2006) 1.45
Caught in the act: the structure of phosphorylated beta-phosphoglucomutase from Lactococcus lactis. Biochemistry (2002) 1.43
N-(3-oxo-acyl)homoserine lactones signal cell activation through a mechanism distinct from the canonical pathogen-associated molecular pattern recognition receptor pathways. J Biol Chem (2006) 1.42
Immunopharmacotherapy: vaccination strategies as a treatment for drug abuse and dependence. Pharmacol Biochem Behav (2009) 1.39
MPZP: a novel small molecule corticotropin-releasing factor type 1 receptor (CRF1) antagonist. Pharmacol Biochem Behav (2007) 1.39
Toward the discovery of potent inhibitors of botulinum neurotoxin A: development of a robust LC MS based assay operational from low to subnanomolar enzyme concentrations. Chem Commun (Camb) (2008) 1.37
Investigations using immunization to attenuate the psychoactive effects of nicotine. Bioorg Med Chem (2004) 1.37
Mechanistic studies of a peptidic GRP78 ligand for cancer cell-specific drug delivery. Mol Pharm (2007) 1.35
The origin of the electrostatic perturbation in acetoacetate decarboxylase. Nature (2009) 1.34
Histidine kinases as targets for new antimicrobial agents. Bioorg Med Chem (2002) 1.33
Impact of distinct chemical structures for the development of a methamphetamine vaccine. J Am Chem Soc (2011) 1.31
Structure and activity analyses of Escherichia coli K-12 NagD provide insight into the evolution of biochemical function in the haloalkanoic acid dehalogenase superfamily. Biochemistry (2006) 1.31
Synthesis and biological validation of a ubiquitous quorum-sensing molecule. Angew Chem Int Ed Engl (2004) 1.29
HAD superfamily phosphotransferase substrate diversification: structure and function analysis of HAD subclass IIB sugar phosphatase BT4131. Biochemistry (2005) 1.29
The use of small molecules to investigate molecular mechanisms and therapeutic targets for treatment of botulinum neurotoxin A intoxication. ACS Chem Biol (2006) 1.26
A critical evaluation of a nicotine vaccine within a self-administration behavioral model. Mol Pharm (2010) 1.26
Bimodal modulation of the botulinum neurotoxin protein-conducting channel. Proc Natl Acad Sci U S A (2009) 1.26
Identification of a botulinum neurotoxin A protease inhibitor displaying efficacy in a cellular model. Chem Commun (Camb) (2006) 1.25
Dynamic vaccine blocks relapse to compulsive intake of heroin. Proc Natl Acad Sci U S A (2013) 1.24
The X-ray crystal structures of human alpha-phosphomannomutase 1 reveal the structural basis of congenital disorder of glycosylation type 1a. J Biol Chem (2006) 1.22
Combinatorial antibody libraries from cancer patients yield ligand-mimetic Arg-Gly-Asp-containing immunoglobulins that inhibit breast cancer metastasis. Proc Natl Acad Sci U S A (2004) 1.21
Analysis of the substrate specificity loop of the HAD superfamily cap domain. Biochemistry (2004) 1.20
A credit-card library approach for disrupting protein-protein interactions. Bioorg Med Chem (2005) 1.20
The catalytic scaffold of the haloalkanoic acid dehalogenase enzyme superfamily acts as a mold for the trigonal bipyramidal transition state. Proc Natl Acad Sci U S A (2008) 1.19
Structural origin of the high affinity of a chemically evolved lanthanide-binding peptide. Angew Chem Int Ed Engl (2004) 1.19
Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose. Pharmacol Biochem Behav (2005) 1.19
Synthesis and structure-activity relationships of second-generation hydroxamate botulinum neurotoxin A protease inhibitors. Bioorg Med Chem Lett (2007) 1.19
Cocaine analog coupled to disrupted adenovirus: a vaccine strategy to evoke high-titer immunity against addictive drugs. Mol Ther (2011) 1.18
A method for the generation of combinatorial antibody libraries using pIX phage display. Proc Natl Acad Sci U S A (2002) 1.18
Catalytic features of the botulinum neurotoxin A light chain revealed by high resolution structure of an inhibitory peptide complex. Biochemistry (2008) 1.17
Interspecies and interkingdom communication mediated by bacterial quorum sensing. Chem Soc Rev (2008) 1.17
Botulinum neurotoxin A protease: discovery of natural product exosite inhibitors. J Am Chem Soc (2010) 1.14
An unexpected switch in the modulation of AI-2-based quorum sensing discovered through synthetic 4,5-dihydroxy-2,3-pentanedione analogues. J Am Chem Soc (2008) 1.14
Aptamer selection by high-throughput sequencing and informatic analysis. Biotechniques (2011) 1.14
Antibody interference with N-acyl homoserine lactone-mediated bacterial quorum sensing. J Am Chem Soc (2006) 1.13
Analysis of epitope information related to Bacillus anthracis and Clostridium botulinum. Expert Rev Vaccines (2008) 1.13
Structural basis for ligand recognition and discrimination of a quorum-quenching antibody. J Biol Chem (2011) 1.13
Defining the mode of action of tetramic acid antibacterials derived from Pseudomonas aeruginosa quorum sensing signals. J Am Chem Soc (2009) 1.12
A methamphetamine vaccine attenuates methamphetamine-induced disruptions in thermoregulation and activity in rats. Biol Psychiatry (2012) 1.11
Design of a heterospecific, tetrameric, 21-residue miniprotein with mixed alpha/beta structure. Structure (2005) 1.11
Development of immunopharmacotherapy against drugs of abuse. Curr Drug Discov Technol (2004) 1.10
N-H insertion reactions of primary ureas: the synthesis of highly substituted imidazolones and imidazoles from diazocarbonyls. J Org Chem (2004) 1.09
A molecular link between the active component of marijuana and Alzheimer's disease pathology. Mol Pharm (2006) 1.09
The 2.1 A structure of Torpedo californica creatine kinase complexed with the ADP-Mg(2+)-NO(3)(-)-creatine transition-state analogue complex. Biochemistry (2002) 1.09
Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms. Cancer Res (2006) 1.08
Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1. FEBS Lett (2010) 1.07
Novel cocaine vaccine linked to a disrupted adenovirus gene transfer vector blocks cocaine psychostimulant and reinforcing effects. Neuropsychopharmacology (2011) 1.07
Medicinal chemistry as a conduit for the modulation of quorum sensing. J Med Chem (2010) 1.06
Total synthesis of the depsipeptide FR-901375. J Org Chem (2003) 1.06
Chemical confirmation of a pentavalent phosphorane in complex with beta-phosphoglucomutase. J Am Chem Soc (2005) 1.05
Catalytic cycling in beta-phosphoglucomutase: a kinetic and structural analysis. Biochemistry (2005) 1.05
Tissue factor-activated coagulation cascade in the tumor microenvironment is critical for tumor progression and an effective target for therapy. Cancer Res (2011) 1.04
Quaternary ammonium oxidative demethylation: X-ray crystallographic, resonance Raman, and UV-visible spectroscopic analysis of a Rieske-type demethylase. J Am Chem Soc (2012) 1.04
Soluble polymers as scaffolds for recoverable catalysts and reagents. Chem Rev (2002) 1.04
Recent advances in enantioselective [2 + 2 + 2] cycloaddition. Org Biomol Chem (2008) 1.04
Light chain of botulinum neurotoxin serotype A: structural resolution of a catalytic intermediate. Biochemistry (2006) 1.04
Analysis of the structural determinants underlying discrimination between substrate and solvent in beta-phosphoglucomutase catalysis. Biochemistry (2009) 1.04
Pharmacophore reassignment for induction of the immunosurveillance cytokine TRAIL. Angew Chem Int Ed Engl (2014) 1.03
Inducing apoptosis in chemotherapy-resistant B-lineage acute lymphoblastic leukaemia cells by targeting HSPA5, a master regulator of the anti-apoptotic unfolded protein response signalling network. Br J Haematol (2011) 1.02
Engineering encodable lanthanide-binding tags into loop regions of proteins. J Am Chem Soc (2011) 1.02
A previously undescribed chemical link between smoking and metabolic disease. Proc Natl Acad Sci U S A (2002) 1.02
Cocaine pharmacology and current pharmacotherapies for its abuse. Bioorg Med Chem (2004) 1.02
Human antibodies against spores of the genus Bacillus: a model study for detection of and protection against anthrax and the bioterrorist threat. Proc Natl Acad Sci U S A (2002) 1.01
A new strategy for improved nicotine vaccines using conformationally constrained haptens. J Am Chem Soc (2003) 1.00
Structural determinants of substrate recognition in the HAD superfamily member D-glycero-D-manno-heptose-1,7-bisphosphate phosphatase (GmhB) . Biochemistry (2010) 1.00
Repositioning of an existing drug for the neglected tropical disease Onchocerciasis. Proc Natl Acad Sci U S A (2010) 1.00
NB2001, a novel antibacterial agent with broad-spectrum activity and enhanced potency against beta-lactamase-producing strains. Antimicrob Agents Chemother (2002) 0.99
Chirality holds the key for potent inhibition of the botulinum neurotoxin serotype a protease. Org Lett (2010) 0.99
Identification and characterization of single chain anti-cocaine catalytic antibodies. J Mol Biol (2006) 0.99